Abstract:Despite a decrease in prevalence and incidence rates, beta thalassemia continues to represent a significant public health challenge worldwide. In high-resource settings, children with thalassemia have an open prognosis, with a high chance of reaching adulthood and old age with a good quality of life. This is achievable if transfusion therapy is properly managed, effectively mitigating ineffective erythropoiesis and its associated complications while also minimizing excessive iron accumulation. Adequate iron chelation is essential to maintain reactive forms of iron within the normal range throughout life, thus preventing organ damage caused by hemosiderosis, which inevitably results from a regular transfusion regimen. New therapies, both curative, such as gene therapy, and non-curative, such as modulators of erythropoiesis, are becoming available for patients with transfusion-dependent beta thalassemia. Two curative approaches based on gene therapy have been investigated in both adults and children with thalassemia. The first approach uses a lentivirus to correct the genetic defect, delivering a functional gene copy to the patient's cells. The second approach employs CRISPR/Cas9 gene editing to directly modify the defective gene at the molecular level. No non-curative therapies have received approval for pediatric use. Among adults, the only available drug is luspatercept, which is currently undergoing clinical trials in pediatric populations. However, in many countries around the world, the new therapeutic options remain a mirage, and even transfusion therapy itself is not guaranteed for most patients, while the choice of iron chelation therapy depends on drug availability and affordability.

Rheumatological complications of beta-thalassaemia: an overview

Endocrinopathies in beta thalassemia: a narrative review

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation

How I manage medical complications of β-thalassemia in adults

Arrhythmias and Sudden Cardiac Death in Beta-Thalassemia Major Patients: Noninvasive Diagnostic Tools and Early Markers

Current status of beta‐thalassemia and its treatment strategies

Αlpha-thalassemia: A practical overview

Bone disease in β thalassemia patients: past, present and future perspectives

Thalassaemia-A global view

Revisiting beta thalassemia intermedia: past, present, and future prospects

Mortality and complications in Omani patients with beta-thalassemia major: a long-term follow-up study

Cardiac complications and iron overload in beta thalassemia major patients—a systematic review and meta-analysis

Skin complications during iron chelation therapy for beta-thalassemia: overview and treatment approach

Cardiac complications in thalassemia throughout the lifespan: Victories and challenges

Role of Curcumin in Beta Thalassemia: A Review

The role of extracellular vesicles on the occurrence of clinical complications in β-thalassemia

Iron overload: the Achilles heel of β- thalassemia

Established Approaches, Old Issues, New Non-Curative Therapies, and Perspectives on Healing

Complications of β-thalassemia major in North America

Growth and endocrinopathies among children with β-Thalassemia major treated at Dubai Thalassemia centre

Evaluation of some nonroutine cardiac biomarkers among adults and children with beta-thalassemia major